Macquarie Group LTD Beam Therapeutics Inc. Transaction History

Macquarie Group LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $20,292 - $35,858	-510 Closed	0 $24,000
Q4 2021 Feb 11, 2022	BUY	$68.02 - $99.06 $17,821 - $25,953	262 Added 105.65%	510 $41,000
Q1 2021 May 14, 2021	SELL	$71.28 - $120.75 $8,339 - $14,127	-117 Reduced 32.05%	248 $20,000
Q2 2020 Aug 11, 2020	BUY	$15.26 - $28.66 $5,569 - $10,460	365 New	365 $10,000

232

75.3M

392K

202K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.85B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.